Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy

Immunological Reviews

Volumn 217, Issue 1, 2007, Pages 38-52

  Eklund, Kari K ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Drug therapy; Mast cell; Rheumatic diseases

Indexed keywords

AMYLOID A PROTEIN; ANTIHISTAMINIC AGENT; ANTIRHEUMATIC AGENT; CYTOKINE; GLUCOCORTICOID; PROTEIN TYROSINE KINASE; PROTEINASE; SERUM AMYLOID A; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AMYLOIDOSIS; CELL ACTIVATION; CONNECTIVE TISSUE DISEASE; DRUG MECHANISM; HUMAN; MAST CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SPONDYLOARTHROPATHY; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

AMYLOIDOSIS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CONNECTIVE TISSUE DISEASES; HUMANS; MAST CELLS; RHEUMATIC DISEASES; SERUM AMYLOID A PROTEIN;

EID: 34248186535     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2007.00504.x     Document Type: Review

References (114)

1. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991 10 : 4025 4031.
2. Horai R, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000 19 : 313 320.
3. Ji H, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002 196 : 77 85.
4. Ruddy S, Britton MC, Schur PH, Austen KF. Complement components in synovial fluid: activation and fixation in seropositive rheumatoid arthritis. Ann NY Acad Sci 1969 168 : 161 172.
5. Schur PH, Britton MC, Franco AE, Corson JM, Sosman JL, Ruddy S. Rheumatoid synovitis: complement and immune complexes. Rheumatology 1975 6 : 34 42.
6. Newkirk M. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 2002 104 : 1 13.
7. Nigrovic PA, Lee DM. Mast cells in inflammatory arthritis. Arthritis Res Ther 2005 7 : 1 11.
8. Mandik-Nayak L, Allen PM. Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis. Immunol Res 2005 32 : 5 13.
9. Korganow AS, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity1999 10 : 451 461.
10. Corr M, Crain B. The role of FcγR signaling in the K/B × N serum transfer model of arthritis. J Immunol 2002 169 : 6604 6669.
11. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner M. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002 297 : 1689 1692.
12. Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001 167 : 1601 1608.
13. Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H. A crucial role for macrophages in the pathology of K/B × N serum-induced arthritis. Eur J Immunol 2005 35 : 3064 3073.
14. Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003 4 : 974 981.
15. Tager AM, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003 4 : 982 990.
16. Malaviya R, Twesten NJ, Ross EA, Abraham SN, Pfeifer JD. Mast cells process bacterial Ags through a phagocytic route for to class I MHC presentation to T cells. J Immunol 1996 156 : 1490 1496.
17. Taube C, et al. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006 176 : 3157 3164.
18. Crisp AJ, Chapman CM, Kirkham SE, Schiller AL, Krane SM. Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum 1984 27 : 845 851.
19. Gruber BL, Poznansky M, Boss E, Partin J, Gorevic P, Kaplan AP. Characterization and functional studies of rheumatoid synovial mast cells. Arthritis Rheum 1986 29 : 944 955.
20. Bromley M, Wooley DE. Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum 1984 27 : 857 863.
21. Gotis-Graham I, Smith MD, Parker A, McNeil HP. Synovial mast cells responses during clinical improvement in early rheumatoid arthritis. Ann Rheum Dis 1998 57 : 664 671.
22. De Paulis A, et al. Human synovial mast cells. I. Ultrastructural in situ and in vitro immunologic characterization. Arthritis Rheum 1996 39 : 1222 1233.
23. Juurikivi A, et al. Induction of apoptosis in mast cells in rheumatoid synovia by inhibiting c-Kit tyrosine kinase: a potential approach for treatment of arthritis. Ann Rheum Dis 2005 64 : 1126 1131.
24. Ceponis A, et al. Expression of stem cell factor (SCF) and SCF receptor (c-Kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol 1998 25 : 2304 2314.
25. Malone DG, Wilder RL, Saavedra-Delgado AM, Metcalfe DD. Mast cell numbers in rheumatoid synovial tissues. Arthritis Rheum 1987 30 : 130 137.
26. Mican JM, Metcalfe DD. Arthritis and mast cell activation. J Allergy Clin Immunol 1990 86 : 677 683.
27. Chatpar PC, Muller D, Gruber B, Kaplan AP, Gorevic PD. Prevalence of IgE rheumatoid factor (IgE RF) in mixed cryoglobulinemia and rheumatoid arthritis. Clin Exp Rheumatol 1986 4 : 313 317.
28. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high affinity IgG receptor, FcgRI, on human mast cells: upregulation by IFN-g. J Immunol 2000 164 : 4332 4339.
29. Okayama Y, Hagaman DD, Metcalfe DD. A comparison of mediators released or generated by IFN-γ-treated human mast cells following aggregation of FcγRI or FcεRI. J Immunol 2001 166 : 4705 4712.
30. Woolhiser MR, Brockow K, Metcalfe DD. Activation of human mast cells by aggregated IgG through FcgRI: additive effects of C3a. Clin Immunol 2004 110 : 172 180.
31. Zhang Y, Ramos BF, Jakschik BA. Augmentation of reverse Arthus reaction by mast cells in mice. J Clin Invest 1991 88 : 841 846.
32. Kiener HP, et al. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 1998 41 : 233 245.
33. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor2 activators selectively induce different classes of mediator production from human mast cells. J Immunol 2003 170 : 1625 1629.
34. van der Heijden IM, et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000 43 : 593 598.
35. Toivanen P. Normal intestinal microbiota in the aetiopathogenesis of rheumatoid arthritis. Ann Rheum Dis 2003 62 : 807 811.
36. Buckley MG, et al. Mast cell activation in arthritis: detection of alpha- and beta-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci 1997 93 : 363 370.
37. Malone DG, Irani A-M, Schwartz LB, Barrett KE, Metcalfe DD. Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis Rheum 1986 29 : 956 963.
38. Konttinen YT, Li TF, Hukkanen M, Ma J, Xu JW, Virtanen I. Fibroblast biology: signals targeting the synovial fibroblast in arthritis. Arthritis Res 2000 2 : 348 355.
39. Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 1991 88 : 493 499.
40. Garbuzenko E, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002 32 : 237 246.
41. Gitter BD, Labus JM, Lees SL, Scheetz ME. Characteristics of human synovial fibroblast activation by IL-1 beta and TNF alpha. Immunology 1989 66 : 196 200.
42. Kiener HP, et al. Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum 2000 43 : 164 174.
43. Tetlow LC, Woolley DE. Mast cells, cytokines and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis 1995 54 : 896 903.
44. Tetlow LC, Harper N, Dunningham T, Morris MA, Bertfield H, Woolley DE. Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis 1998 57 : 25 32.
45. Tetlow LC, Woolley DE. Histamine stimulates matrix metalloproteinase-3 and -13 production by human articular chondrocytes in vitro. Ann Rheum Dis 2002 61 : 737 740.
46. Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu 83-Thr84 bond by mast cell chymase. J Biol Chem 1994 269 : 18134 18140.
47. Gruber BL, Schwartz LB, Ramamurthy NS, Irani AM, Marchese MJ. Activation of latent rheumatoid synovial collagenase by human mast cell tryptase. J Immunol 1988 140 : 3936 3942.
48. Ali AS, et al. Mast cells in atherosclerosis as a source of the cytokine RANKL. Clin Chem Lab Med 2006 44 : 672 674.
49. Norrby K. Mast cells and angiogenesis. APMIS 2002 110 : 355 371.
50. Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech 2003 60 : 64 69.
51. Gordon JR, Galli SJ. Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-α)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses. J Exp Med 1991 174 : 103 107.
52. Woolley DE, Tetlow LC. Mast cell activation and its relation to pro-inflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2000 2 : 65 74.
53. Sandler C, et al. Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-α and IL-β. Inflam Res 2007 (in press).
54. Okamoto H, Nakano K. Regulation of interleukin-1 synthesis by histamine produced by mouse peritoneal macrophages per se. Immunology 1990 69 : 162 165.
55. Yoffe JR, Taylor DJ, Woolley DE. Mast cell products and heparin stimulate the production of mononuclear-cell factor by cultured human monocyte-macrophages. Biochem J 1985 230 : 83 88.
56. De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982 2 : 231 234.
57. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985 21 : 283 287.
58. Westermark GT, Engstrom U, Westermark P. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 1992 182 : 27 33.
59. Kluve-Beckerman B, Liepnieks JJ, Wang L, Benson MD. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol 1999 155 : 123 133.
60. Toth T, Toth-Jakatics R, Jimi S, Takebayashi S. Increased density of interstitial mast cells in amyloid A renal amyloidosis. Mol Pathol 2000 13 : 1020 1029.
61. Olsson N, Siegbahn A, Nilsson G. Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway. Biochem Biophys Res Commun 1999 254 : 143 146.
62. Niemi K, Baumann MH, Kovanen PT, Eklund KK. Serum amyloid A (SAA) activates human mast cells which leads into degradation of SAA and generation of an amyloidogenic SAA fragment. Biochim Biophys Acta 2006 1762 : 424 430.
63. von Bierbrauer A, Barth P, Willert J, Baerwald C, Mennel HD, Schmidt JA. Electron microscopy and capillaroscopically guided nailfold biopsy in connective tissue diseases: detection of ultrastructural changes of the microcirculatory vessels. Br J Rheumatol 1998 37 : 1272 1278.
64. Baroni SS, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006 354 : 2667 2676.
65. Dileepan KN, Stechschulte DJ. Endothelial cell activation by mast cell mediators. Methods Mol Biol 2006 315 : 275 294.
66. Latti S, Leskinen M, Shiota N, Wang Y, Kovanen PT, Lindstedt KA. Mast cell-mediated apoptosis of endothelial cells in vitro: a paracrine mechanism involving TNF-α-mediated down-regulation of bcl-2 expression. J Cell Physiol 2003 195 : 130 138.
67. Leskinen MJ, et al. Mast cell chymase induces smooth muscle cell apoptosis by disrupting NF-kappaB-mediated survival signaling. Exp Cell Res 2006 312 : 1289 1298.
68. Nishioka K, Kobayashi Y, Katayama I, Takijiri C. Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987 123 : 205 208.
69. Seibold JR, Giorno RC, Claman HN. Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum 1990 33 : 1702 1729.
70. Wang HW, Tedla N, Hunt JE, Wakefield D, McNeil HP. Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 2005 14 : 295 302.
71. Chanez P, et al. Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung. Am Rev Respir Dis 1993 147 : 1497 1502.
72. Walker M, Harley R, LeRoy EC. Ketotifen prevents skin fibrosis in the tight skin mouse. J Rheumatol 1990 17 : 57 59.
73. Shiota N, Kakizoe E, Shimoura K, Tanaka T, Okunishi H. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br J Pharmacol 2005 145 : 424 431.
74. Gruber BL, Kaufman LD. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 1991 34 : 362 366.
75. Kubes P, Granger DN. Leukocyte-endothelial cell interactions evoked by mast cells. Cardiovasc Res 1996 32 : 699 708.
76. Metsarinne KP, et al. Activated mast cells increase the level of endothelin-1 mRNA in cocultured endothelial cells and degrade the secreted Peptide. Arterioscler Thromb Vasc Biol 2002 22 : 268 273.
77. Johnston B, Burns AR, Kubes P. A role for mast cells in the development of adjuvant-induced vasculitis and arthritis. Am J Pathol 1998 152 : 555 563.
78. Watanabe N, et al. Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fcgamma receptors. Blood 1999 94 : 3855 3863.
79. Sylvestre DL, Ravetch JV. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 1996 5 : 387 390.
80. Gruber BL, Kaufman LD, Marchese MJ, Roth W, Kaplan AP. Anti-IgE autoantibodies in systemic lupus erythematosus. Prevalence and biologic activity. Arthritis Rheum 1988 31 : 1000 1006.
81. Nagpal S, Sriramarao P, Krishnaswamy PR, Metcalfe DD, Rao PV. Demonstration of IgE antibodies to nucleic acid antigens in patients with SLE. Autoimmunity 1990 8 : 59 64.
82. Hiromura K, Kurosawa M, Yano S, Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis 1998 32 : 593 599.
83. Lin L, Gerth AJ, Peng SL. Susceptibility of mast cell-deficient W/Wv mice to pristine-induced experimental lupus nephritis. Immunol Lett 2004 91 : 93 97.
84. Kanamaru Y, et al. Mast cell-mediated remodeling and fibrinolytic activity protect against fatal glomerulonephritis. J Immunol 2006 176 : 5607 5615.
85. Eklund KK, et al. Glucocorticoids inhibit the cytokine-induced proliferation of mast cells, the high affinity IgE receptor-mediated expression of TNF-a, and the IL-10-induced expression of chymases. J Immunol 1997 158 : 4373 4380.
86. Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-Kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 1997 99 : 1721 1728.
87. Lippert U, Welker P, Kruger-Krasagakes S, Moller A, Henz BM. Modulation in vitro cytokine release from leukemic mast cells (HMC-1) by glucocorticoids. Skin Pharmacol 1996 9 : 93 98.
88. Cohan VL, Undem BJ, Fox CC, Adkinson NF Jr., Lichtenstein LM, Schleimer RP. Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. Am Rev Respir Dis 1989 140 : 951 954.
89. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006 368 : 780 793.
90. Kobayashi Y, Okunishi H. Mast cell in rheumatoid arthritis. Jpn J Pharmacol 2002 90 : 7 11.
91. O'Dell JR, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001 44 : 2235 2241.
92. Sandler C, et al. Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C. Inflamm Res 2005 54 : 304 312.
93. Sandler C, et al. Chemically modified tetracyclines induce apoptosis in cultured mast cells. Int Immunopharmacol 2005 5 : 1611 1621.
94. Xiang Z, Ahmed AA, Moller C, Nakayama K, Hatakeyama S, Nilsson G. Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation. J Exp Med 2001 194 : 1561 1569.
95. Berent-Maoz B, Piliponsky AM, Daigle I, Simon HU, Levi-Schaffer F. Human mast cells undergo TRAIL-induced apoptosis. J Immunol 2006 176 : 2272 2278.
96. Cirillo R, de Paulis A, Ciccarelli A, Triggiani M, Marone G. Ciclosporin A inhibits mediator release from human Fc epsilon RI+ cells by interacting with cyclophilin. Int Arch Allergy Appl Immunol 1991 94 : 76 77.
97. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol 1994 153 : 3717 3723.
98. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006 533 : 327 340.
99. Iemura A, Tsai M, Ando A, Wershil BK, Galli SJ. The c-Kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 1994 144 : 3211 3218.
100. Yarden Y, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987 6 : 3341 3351.
101. Buchdunger E, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000 295 : 139 145.
102. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-Kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000 96 : 925 932.
103. Druker BJ, et al. Effects of selective inhibitor of the Abl tyrosine kinase on the growth of BCR-Abl positive cells. Nat Med 1996 2 : 561 566.
104. Akin C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-Kit. Exp Hematol 2003 31 : 686 692.
105. Zermati Y, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-Kit receptors found in mast cell neoplasms. Oncogene 2003 22 : 660 664.
106. Eklund KK, et al. Maintained efficacy of tyrosine kinase inhibitor imatinib mesylate in the treatment of rheumatoid arthritis. J Clin Rheumatol 2007 (in press).
107. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med 2003 35 : 362 367.
108. Paniagua RT, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006 116 : 2633 2642.
109. Ando W, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 2006 24 : 274 282.
110. Bischoff SC, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996 28 : 1 13.
111. Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002 16 : 537 549.
112. Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M. Three months treatment of active spondyloarthritis with imatinib mesylate: an open label pilot study with six patients. Rheumatology 2006 45 : 1573 1575.
113. Dewar AL, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005 105 : 3127 3132.
114. Sandler C, Joutsiniemi S, Lindstedt K, Kovanen P, Juutilainen T, Eklund KK. Imatinib mesylate inhibits platelet derived growth factor induced proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun 2006 347 : 31 35.